See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Carnival Corporation (CCL) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Carnival Corporation (CCL) - free report >>
Why is Norwegian Cruise Line (NCLH) Plummeting Today?
On Tuesday, shares of embattled cruise company Norwegian Cruise Line (NCLH - Free Report) plummeted. The stock was down about 19% in late morning trading after it warned that it may have to seek bankruptcy protection.
NCL was down 22.5% at the closing bell.
Norwegian said in an SEC filing that there’s “substantial doubt” about its ability to continue as a business. The company had roughly $6 billion in long-term debt as of Dec. 31, and if Norwegian can’t amend its credit agreements, it said it would be at risk for default.
Because of the Covid-19 pandemic, Norwegian had to suspend its entire fleet beginning March 14, and the shutdown has now been extended through at least June 30. The company also furloughed 20% of its shoreside staff.
The pandemic has hit the cruise industry particularly hard, with Royal Carribbean (RCL - Free Report) and Carnival (CCL - Free Report) forced to shut down operations as well.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>